Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST-Reference-Cited by-同舟云学术

Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST

Published:2012-04 Issue:4 Volume:198 Page:737-745
ISSN:0361-803X
Container-title:American Journal of Roentgenology
language:en
Short-container-title:American Journal of Roentgenology

Author:

Nishino Mizuki,Jagannathan Jyothi P.,Krajewski Katherine M.,O’Regan Kevin,Hatabu Hiroto,Shapiro Geoffrey,Ramaiya Nikhil H.

Publisher

American Roentgen Ray Society

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference55 articles.

1. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

2. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

3. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

4. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

5. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative peritumoral magnetic resonance imaging fingerprinting improves machine learning-based prediction of overall survival in colorectal cancer;Exploration of Targeted Anti-tumor Therapy;2024-02-19

2. Imaging in Oncology;Tata Memorial Centre Textbook of Oncology;2024

3. Delta-radiomics in cancer immunotherapy response prediction: A systematic review;European Journal of Radiology Open;2023-12

4. Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer;European Urology Oncology;2023-12

5. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150;Tumor Biology;2023-08-02